Cancer Antigens
Cancer Antigens 125 (CA-125), 72-4 (CA 72-4), 19-9 (CA 19-9), and 15-3 (CA 15-3) are tumor markers used in oncology to monitor treatment response and detect potential recurrences in various cancers.
CA-125 is often associated with ovarian cancer, CA 72-4 with gastrointestinal cancers, CA 19-9 with pancreatic and gastrointestinal cancers, and CA 15-3 is mainly associated with breast cancer.
These markers are not definitive for cancer diagnosis but can provide valuable information on disease progression and treatment efficacy when used in conjunction with other diagnostic methods.
Cancer antigens are derived from native serum, ascites, tumors, and seminal fluid
Cancer Antigen 125 General Spec Sheet
Cancer Antigen 72-4 General Spec Sheet
Cancer Antigens 125 (CA-125), 72-4 (CA 72-4), 19-9 (CA 19-9), and 15-3 (CA 15-3) are tumor markers used in oncology to monitor treatment response and detect potential recurrences in various cancers.
CA-125 is often associated with ovarian cancer, CA 72-4 with gastrointestinal cancers, CA 19-9 with pancreatic and gastrointestinal cancers, and CA 15-3 is mainly associated with breast cancer.
These markers are not definitive for cancer diagnosis but can provide valuable information on disease progression and treatment efficacy when used in conjunction with other diagnostic methods.
Cancer antigens are derived from native serum, ascites, tumors, and seminal fluid
Cancer Antigen 125 General Spec Sheet
Cancer Antigen 72-4 General Spec Sheet
Cancer Antigens 125 (CA-125), 72-4 (CA 72-4), 19-9 (CA 19-9), and 15-3 (CA 15-3) are tumor markers used in oncology to monitor treatment response and detect potential recurrences in various cancers.
CA-125 is often associated with ovarian cancer, CA 72-4 with gastrointestinal cancers, CA 19-9 with pancreatic and gastrointestinal cancers, and CA 15-3 is mainly associated with breast cancer.
These markers are not definitive for cancer diagnosis but can provide valuable information on disease progression and treatment efficacy when used in conjunction with other diagnostic methods.
Cancer antigens are derived from native serum, ascites, tumors, and seminal fluid
Cancer Antigen 125 General Spec Sheet
Cancer Antigen 72-4 General Spec Sheet
Testing:
The Cell Line Supernatant was tested and found non-reactive for HIV 1/2, HBsAg, HCV, HIV-1 (NAT) and HCV (NAT) by current FDA methods. Please note that the samples tested were Cell Culture Supernatants, not serum and not appropriate for use in these assays.
Intended Use and Customer Responsibility
Golden West BioSolutions, LLC products are specifically designed for research and the manufacturing of non-injectable products. It is the customer's responsibility to handle these products safely and responsibly. Golden West BioSolutions, LLC is not liable for any injuries stemming from the use or handling of its products. All disposal procedures must align with federal and state regulations.
Quality Assurance Disclaimer
Golden West BioSolutions, LLC does not warrant the performance of their products in specific applications. Customers are responsible for determining the suitability and qualification of Golden West BioSolution products for their intended use. Given the natural variation in biological materials, Golden West BioSolutions, LLC also recommends consideration of lot-to-lot evaluation.